Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyramza plus Keytruda in Advanced Gastric, Lung, Urothelial, or Biliary Tract Cancers
NCT02443324Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2015
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of ramucirumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, non-small cell lung cancer (NSCLC) and 2 more (7 arms), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Jul 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomanon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02443324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443324.